Asthma
Conditions
Keywords
respiratory, combination treatment, Elpenhaler, Diskus
Brief summary
The aim of this study is to establish the therapeutic equivalence between the test (Fluticasone/Salmeterol administered with Elpenhaler®db, Rolenium®) and the reference formulation (Seretide®, administered with Diskus®), both containing 250/50μg of the Fluticasone/Salmeterol combination. In case of inhaled products, it is not possible to follow the classic scheme, based on similarity of plasma concentration-time behavior of parent drug in assessing bioequivalence.
Detailed description
A pharmacodynamic study was designed in order to assess the therapeutic equivalence of the new formulation of Fluticasone/Salmeterol with the innovative one. The test and reference Fluticasone/Salmeterol formulations will be compared in terms of their bronchodilator effects in lung function. Forced Expiratory Volume in 1 second (FEV1) will be the primary efficacy measure and will be measured in such a way that a similar time-dependent increase in pulmonary function can be demonstrated for both Fluticasone/Salmeterol formulations in patients with asthma. In terms of safety comparison, repeated measurements of adverse events, vital signs, heart rate, blood hematology and biochemistry as well as ECG changes will enable the establishment of the similar safety profile of the test and reference Fluticasone/Salmeterol combinations. The study will be conducted in a randomized, double-blind, double-dummy, placebo-controlled, 3x3 crossover fashion.
Interventions
DEVICERP - TA
randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
Sponsors
Elpen Pharmaceutical Co. Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age 18-65 years, * diagnosis of asthma of 6 months, * FEV1 ≥ 50% and ≤ 80% predicted, reversibility of at least 12%, * stable asthma for at least 4 weeks, * inhaled steroids (ICS) at a stable dose within the previous 30 days, * PIF 30 - 90 lt/min and * informed consent.
Exclusion criteria
* history of other pulmonary disease, asthma exacerbation or respiratory infection within the previous 4 weeks, * hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral steroid dose increase within the previous 30 days, * heavy smokers, * change of asthma medication within the previous 4 weeks, seasonal asthma alone, * history of severe heart disease, * pregnancy or lactation, * use of a β-blocker, of a NSAID or an antiallergic/antihistaminic medication within 2 weeks prior to screening visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FEV1 | 8 days | 12-hour average FEV1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 8 days | Number of Adverse Events during the study |
Outcome results
None listed